Researchers at Brigham and Women’s Hospital and Dana-Farber Cancer Institute found significant uptake and scalability in phone-based “PATH” intervention to improve psychological well-being in blood cancer patients, according to new study in JNCCN.
New study shows UC Davis total-body advanced PET scanner EXPLORER can visualize dual blood supply in lungs and effectively evaluate lung cancer and track treatment progress.
As many as 40% of preterm infants in the U.S. suffer from nephrocalcinosis, a condition that deposits excess calcium in kidneys.
Roswell Park Comprehensive Cancer Center has earned its most highly rated grant from the National Cancer Institute (NCI). The NCI renewed Roswell Park’s status as a Comprehensive Cancer Center - a designation held by less than 4% of cancer centers- awarding Roswell Park the highest possible “Exceptional” rating as it renewed a grant Roswell Park has successfully competed for since 1972.
Bioengineering is revolutionizing cancer research, and Moffitt Cancer Center is at the forefront of this transformative movement. Moffitt is the first National Cancer Institute-designated comprehensive cancer center with a dedicated bioengineering department. This area of science integrates engineering and physical sciences with oncology to change how we understand and treat this complex disease.
The UC Davis Department of Obstetrics and Gynecology is recruiting potential participants for a clinical trial of an investigational hormone-free monthly intravaginal method of contraception.
In a groundbreaking advance that could revolutionize bladder cancer treatment, a novel combination of cretostimogene grenadenorepvec and pembrolizumab has shown remarkable efficacy in patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news. March is Colorectal Cancer Awareness Month, contact our media team to set up interviews.
Study finds that mesalamine, a common anti-inflammatory drug, can fight the fungus Candida albicans in the gut, potentially preventing the risk of invasive candidiasis in patients with blood cancers.
According to preliminary data from a multi-institution Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, intensity modulated proton therapy (IMPT) achieved similar clinical outcomes and offered significant patient benefits when compared to traditional intensity modulated radiation therapy (IMRT) as part of chemoradiation treatment for patients with oropharyngeal (head and neck) cancer.
Over the last two decades, strides in cancer prevention, earlier detection, and novel treatments have reduced overall cancer mortality; however, cancer health disparities (CHD) persist among demographically diverse and intersecting populations.
A novel immunotherapy approach developed by Ludwig Cancer Research scientists employs a two-pronged attack against solid tumors to boost the immune system’s ability to target and eliminate cancer cells.
Based on an analysis of data from a regional cancer center, Dana-Farber Cancer Institute researchers calculate that, nationwide, cancer care that utilizes telehealth and local care would generate 33.1% less greenhouse gas emissions than the traditional model of in-person care. Study published in JAMA Oncology.
Cancer health disparities are differences in cancer burden experienced by members of marginalized communities. As such, discrimination based on gender identity and/or sexual orientation contributes to cancer disparities today. While data about cancer among members of the LGBTQ+ community is somewhat limited, recent studies have found that members of this group may have an elevated rate of cancer diagnoses. Our experts share more.
Dana-Farber Cancer Institute researchers are leading 3 separate studies with encouraging results in treating patients with central nervous system (CNS) lymphoma, breast cancer, and glioblastoma. These findings are among more than 80 studies presented at ASCO that are led by Dana-Farber-affiliated researchers.
Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Virogen Biotechnology Inc., a clinical-stage biotechnology company, announced a groundbreaking strategic partnership today. This collaboration aims to propel the development of Virogen's cutting-edge fusion protein, VG712 (Resimmune), addressing significant unmet needs in oncology and immunotherapy.
Researchers from The University of Texas MD Anderson Cancer Center presented positive clinical results from two studies today at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Secondary analyses of a phase 3 clinical trial have revealed that breast cancer patients who reported high levels of pain and stress were more likely than their study peers to experience worse invasive disease-free survival (iDFS) and worse overall survival (OS).
Data from a large prospective cohort study reveal that a polygenic risk score has the potential to predict survival outcomes in patients with breast cancer.
20221027104337.jpg&width=400&height=400)
New research from Yale Cancer Center reveals first-of-its-kind data from a phase I study in patients with hormone receptor positive HER2-negative metastatic breast cancer. The results, which assess the safety and efficacy of a treatment known as PF-07248144, offer new hope for treating this aggressive type of breast cancer.
A new mouse study of heart failure with preserved ejection fraction (HFpEF) found sex differences at the cellular level. The findings could have implications for how HFpEF is treated in women compared to men.
Researchers from Fred Hutch Cancer Center have found that active surveillance for prostate cancer patients with a low risk of progression is an effective alternative to immediate surgery or radiation to manage the disease.
Four teams of Dana-Farber Cancer Institute investigators have found that people experience discrimination and bias in different ways and in more realms of cancer care than previously understood. The findings, in different studies, suggest that oncology professionals and the systems they work in have more work to do to adapt to the realities of increasing diversity and inclusion, not only in the patient population but also in the oncology workforce.
Published May 28 in Nature Communications, bioengineer Matthias Stephan, MD, PhD, and his Fred Hutch team report that a foaming liquid worked better than a standard liquid formulation at transferring gene therapy components to cells in laboratory studies.
Testosterone fuels the growth of prostate cancer. The target of testosterone is the androgen receptor. Metastatic prostate cancer is treated by reducing levels of testosterone, and despite initial responses to treatment, nearly all patients become resistant to androgen deprivation therapy.
Patients being treated for HPV-related oropharynx cancer might need less radiation therapy typically given post-surgery, according to a new study.
In a study published online ahead of print in Cancer Research, a team of Moffitt Cancer Center researchers introduce a novel framework that leverages deep reinforcement learning to tailor adaptive treatment schedules, potentially doubling the time to progression compared to current standard-of-care protocols.
In honor of their outstanding contributions to the field of oncology, two researchers from The University of MD Anderson Cancer Center will be honored with Special Awards at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
New insights on improving clinical outcomes and quality of life among breast cancer patients highlight the slate of new research presentations Roswell Park Comprehensive Cancer Center experts will deliver at the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place in Chicago next week.
“The COAST study, which we began five years ago, involves patients who get chemotherapy and radiation therapy for lung cancer. And now we know that we can improve the outcome with a drug called durvalumab,” explained Dr. Herbst, who will present the findings at ASCO.
A new study by UC Davis researchers finds key differences in the development of the cortex between autistic boys and girls ages 2-13.
Clinicians and scientists from Rutgers Cancer Institute and RWJBarnabas Health will lead sessions and present their latest discoveries from their innovative cancer research program at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago (and online) from May 30-June 4.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. This special edition features presentations by MD Anderson researchers at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
New research by Dana-Farber Cancer Institute investigators has encouraging news for young women who have survived breast cancer and want to have children.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
An increase in nightmares and hallucinations could signal the onset of autoimmune diseases such as lupus, according to a new study.
Skin Brachytherapy, also called radiation seed therapy, offers a non-invasive radiation therapy solution to complement or replace surgery for certain skin cancers. Rajesh V. Iyer, MD, is a radiation oncologist at RWJBarnabas Health and chairman of radiation oncology at Community Medical Center, shares more about this treatment option for patients.
The National Comprehensive Cancer Network participates in meetings hosted by Maria Sklodowska-Curie National Research Institute of Oncology, the Polish Oncological Society, and Alliance for Innovation to advance work adapting proven cancer treatment guidelines for Poland.
The NCCN Guidelines for Patients: Small Bowel Adenocarcinoma are now available for free download at NCCN.org/patientguidelines, thanks to funding from the NCCN Foundation®.
The study, which joins a growing body of research on end-of-life cancer treatment, published May 16 in JAMA Oncology.
Patients with very advanced solid tumors saw no significant improvement in overall survival after receiving systemic therapy, according to a study published today in JAMA Oncology by researchers at The University of Texas MD Anderson Cancer Center and Yale Cancer Center.
Daniel M. Geynisman, MD, is being announced the new Editor-in-Chief for JNCCN—Journal of the National Comprehensive Cancer Network. Dr. Geynisman, Chief of the Division of Genitourinary Medical Oncology at Fox Chase Cancer Center, has a long history of working with NCCN in a variety of roles.
Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery – significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer (NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center.
The Kansas Institute for Precision Medicine (KIPM) will continue its mission to improve health care by training physicians and scientists in precision medicine and supporting their research, thanks to a renewed Centers of Biomedical Research Excellence (COBRE) award from the National Institute of General Medical Sciences, part of the National Institutes of Health.
Researchers at Fred Hutch Cancer Center have found in pre-clinical studies that an experimental gene therapy for genital and oral herpes removed 90% or more of the infection and suppressed how much virus can be released from an infected individual, which suggests that the therapy would also reduce the spread of the virus.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right